NCT05856058View on ClinicalTrials.gov

To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 29, 2023

Primary Completion Date

July 3, 2023

Study Completion Date

October 9, 2023

Conditions

Graft-versus-host Disease

Interventions

DRUG

SHR0302

SHR0302 oral solution 1 time, SHR0302 tablets 1 time

Trial Locations (1)

100005

Beijing Hospital, Beijing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT05856058 - To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability | Biotech Hunter | Biotech Hunter